(Q33398675)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22157807%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22157807%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

main subject

chronic myeloid leukemia

0 references

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22157807%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Andreas Hochhaus

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22157807%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Oliver Ottmann

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22157807%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

F J Giles

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22157807%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

H M Kantarjian

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22157807%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

P D le Coutre

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22157807%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

M Baccarani

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22157807%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

F-X Mahon

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22157807%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

R E Blakesley

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22157807%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

N J Gallagher

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22157807%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

K Gillis

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22157807%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

S L Goldberg

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22157807%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

13 December 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22157807%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22157807%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22157807%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22157807%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

959-962

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22157807%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2011.355

18 January 2020

exact match

0 references

cites work

Accelerated and blastic phases of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

New directions in the treatment of imatinib failure and/or resistance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Gene expression changes associated with progression and response in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Chronic myeloid leukemia: mechanisms of blastic transformation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Current role of stem cell transplantation in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

siRNA-mediated knock-down of P-glycoprotein expression reveals distinct cellular disposition of anticancer tyrosine kinases inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Activation of the Hedgehog pathway in chronic myelogeneous leukemia patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.355

7 January 2021

Identifiers

DOI

10.1038/LEU.2011.355

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22157807%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

18 January 2020

0 references

1 reference